To determine the risk of developing acute myeloid leukaemia (AML) and multiple myeloma in a cohort of workers exposed to benzene.
The results were used to show the importance of taking specificity of disease into consideration in causation analysis.
Methods-Data were derived from a cohort of workers employed at two Goodyear plants in Ohio in the manufacture of Pliofilm.
Based on data in the Pliofilm study, several papers that examined the relation between exposure to benzene and leukaemia (all cell types combined) have been published.
The results based on AML were compared with those for leukaemia (all cell types combined) published previously.
An exposure response relation was shown between cumulative exposure to benzene and AML.
No increased risk of AML was detected for cumulative exposure to benzene below 200ppm-years (SMR 0.91).
Above 200 ppm-years, risk of AML rose drastically ; reaching a significant SMR of 98.37 for>400ppmyears.
For multiple myeloma, no relation with exposure to benzene was detected.
Conclusion-Analysis specific to AML shows the importance of taking specificity of disease into consideration in causation analysis.
This investigation shows that previous analyses based on all leukaemia cell types combined have incorrectly set the estimated threshold too low, and have underestimated risk above the threshold.
Current regulatory policies that rely on previous analyses based on all leukaemia cell types combined should be re-examined.
Mots-clés Pascal : Benzène, Toxicité, Exposition professionnelle, Leucémie myéloblastique, Homme, Myélome, Multiple, Carcinogène, Ohio, Etats Unis, Amérique du Nord, Amérique, Médecine travail, Solvant organique, Aigu, Hémopathie maligne, Lymphoprolifératif syndrome, Immunopathologie, Immunoglobulinopathie
Mots-clés Pascal anglais : Benzene, Toxicity, Occupational exposure, Acute myelocytic leukemia, Human, Myeloma, Multiple, Carcinogen, Ohio, United States, North America, America, Occupational medicine, Organic solvent, Acute, Malignant hemopathy, Lymphoproliferative syndrome, Immunopathology, Immunoglobulinopathy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0384953
Code Inist : 002B19B. Création : 01/03/1996.